A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt,Victoria Wang,Curtis A. Hanson,Neil E. Kay,Susan M. O'Brien,Martin S. Tallman,Jacqueline C Barrientos,Richard M. Stone,Harry P. Erba,Mark R. Litzow

doi:10.1182/blood-2018-120779

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, Victoria Wang + Show 8 more

Open Access

https://doi.org/10.1182/blood-2018-120779

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 53

Affiliation: Stanford University, IIT@Harvard, Mayo Clinic, University of California, Irvine Medical Center, Memorial Sloan Kettering Cancer Center, Hofstra University, Dana-Farber Cancer Institute, University of Alabama at Birmingham

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Full Text